Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 1;12(5):798-803.
doi: 10.21037/hbsn-23-372. Epub 2023 Sep 18.

Review of practice informing data and current state of NCCN consensus guidelines in hepatobiliary cancers

Virginia Corbett  1 , Daneng Li  2 , Aman Chauhan  3
Affiliations
Editorial

Review of practice informing data and current state of NCCN consensus guidelines in hepatobiliary cancers

Virginia Corbett et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: National Comprehensive Cancer Network (NCCN); biliary cancers; hepatocellular carcinoma (HCC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-372/coif). VC reports K12 Paul Calabresi Award in Clinical Oncology and he formerly owned equity in Pfizer, BristolMyers Squibb, Seagen, and Viatris, which are outside the submitted work. DL reports grants from Brooklyn Immunotherapeutics and AstraZeneca, consulting fees from Adagene, AstraZeneca, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Merck, QED, DelCath, TerSera Therapeutics, Sumitomo, TransThera, honorium from Coherus, Servier, Eisai, Exelixis, Ipsen, TerSera and support for attending meetings and/or travel from Genentech. The other author has no conflicts of interest to declare.

Comment on

  • Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD. Benson AB, et al. J Natl Compr Canc Netw. 2021 May 1;19(5):541-565. doi: 10.6004/jnccn.2021.0022. J Natl Compr Canc Netw. 2021. PMID: 34030131

References

    1. Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:541-65. 10.6004/jnccn.2021.0022 - DOI - PubMed
    1. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid 2022;1. doi: .10.1056/EVIDoa2100070 - DOI - PubMed
    1. Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of in-figratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol 2021;39:265. 10.1200/JCO.2021.39.3_suppl.265 - DOI - PubMed
    1. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84. 10.1016/S1470-2045(20)30109-1 - DOI - PMC - PubMed
    1. Zhu AX, Macarulla T, Javle MM, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021;7:1669-77. 10.1001/jamaoncol.2021.3836 - DOI - PMC - PubMed